HUMAN+ is an exquisite opportunity for investors and funders aiming to contribute to more efficient and effective development of pharmaceutical products and diagnostics for patients.
Individual and corporate funders/investors are often confronted with the arduous choice among an array of charities and/or other opportunities to make real impact through their investments. HUMAN+ offers this opportunity in biomedical science, a unique co-financing model to foster high potential research projects and bring the outcomes to patients.
The HUMAN+ business model is ‘lean and mean’, with low overhead costs. Investors and funders are assured that the highest achievable percent of contributions and investments are dedicated to approved projects.
Contributing to, and investing in HUMAN+, allows utilization of a fiscal arrangement with a favorable impact.